Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations Journal Article

Authors: Levine, D. A.; Argenta, P. A.; Yee, C. J.; Marshall, D. S.; Olvera, N.; Bogomolniy, F.; Rahaman, J. A.; Robson, M. E.; Offit, K.; Barakat, R. R.; Soslow, R. A.; Boyd, J.
Article Title: Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations
Abstract: Purpose: The aims of this study were to determine the incidence of BRCA mutations among Ashkenazi Jewish patients with fallopian tube carcinoma (FTC) or primary peritoneal carcinoma (PPC), to study the clinicopathologic features of these cancers, and to estimate the risks of these cancers in association with a BRCA mutation. Patients and Methods: A retrospective review at two institutions identified 29 Jewish patients with FTC and 22 Jewish patients with PPC. These patients were genotyped for the three Ashkenazi Jewish BRCA founder mutations (185delAG and 5382insC in BRCA1 and 6174delT in BRCA2). Surgical and pathologic information, family history, and survival data were obtained from hospital records. All statistical tests were two sided. Results: Germline BRCA mutations were identified in five of 29 patients with FTC (17%) and nine of 22 patients with PPC (41%). Mutation carriers had a younger mean age at diagnosis than patients without a mutation (60 v 70 years; P = .002). The overall median survival was 148 months for mutation carriers and 41 months for patients without a mutation (P = .04). For BRCA mutation carriers, the lifetime risks of FTC and PPC were 0.6% and 1.3%, respectively. Conclusion: Substantial proportions of Ashkenazi Jewish patients with FTC or PPC are BRCA mutation carriers. Patients with BRCA-associated FTC or PPC are younger at diagnosis and have improved survival compared with patients without a BRCA mutation. Although the lifetime risks of FTC or PPC for patients with BRCA heterozygotes are greater than those for the general population, the absolute risks seem relatively low. © 2003 by American Society of Clinical Oncology.
Keywords: adult; cancer survival; controlled study; aged; aged, 80 and over; middle aged; survival rate; retrospective studies; gene mutation; major clinical study; genetics; mutation; clinical feature; clinical trial; review; cancer risk; comparative study; cancer staging; follow up; follow-up studies; neoplasm staging; peritoneum cancer; peritoneal neoplasms; genetic association; genotype; brca1 protein; heterozygote; retrospective study; cancer invasion; oncogene; tumor suppressor gene; dna; genes, brca1; multicenter study; dna, neoplasm; israel; neoplasm invasiveness; uterine tube carcinoma; fallopian tube neoplasms; jews; germ-line mutation; peritoneum tumor; jew; uterine tube tumor; humans; prognosis; human; female; priority journal
Journal Title: Journal of Clinical Oncology
Volume: 21
Issue: 22
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2003-11-15
Start Page: 4222
End Page: 4227
Language: English
DOI: 10.1200/jco.2003.04.131
PUBMED: 14615451
PROVIDER: scopus
Notes: Export Date: 25 September 2014 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Kenneth Offit
    508 Offit
  2. Richard R Barakat
    587 Barakat
  3. Mark E Robson
    365 Robson
  4. Douglas A Levine
    356 Levine
  5. Cindy J Yee
    12 Yee
  6. Jeffrey Boyd
    111 Boyd
  7. Robert Soslow
    641 Soslow
  8. Narciso Olvera
    71 Olvera